CA Patent

CA3234547A1 — Methods and compositions for treatment of polycystic kidney disease

Assigned to Regulus Therapeutics Inc · Expires 2023-04-13 · 3y expired

What this patent protects

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

USPTO Abstract

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Drugs covered by this patent

Patent Metadata

Patent number
CA3234547A1
Jurisdiction
CA
Classification
—
Expires
2023-04-13
Drug substance claim
No
Drug product claim
No
Assignee
Regulus Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.